OBJECTIVE: To (1) assess the prevalence and distribution of on-label telithromycin utilization before and after the revisions of the product label and (2) assess the association of pivotal events in the life cycle of telithromycin with its use as reflected in pharmacy and medical claims. 
RESULTS:
The medical diagnosis analysis consisted of 507 members with 1 or more medical claims with dates of service within 30 days of at least 1 pharmacy claim for telithromycin. Using the original approved telithromycin indications, 52.3% (256 of 507) of telithromycin use was on-label. The most common on-label diagnoses were sinusitis (33.9%) and bronchitis (14.4%). A diagnosis of pneumonia was present for 3.9% of telithromycin utilizers. After the February 12, 2007 , label change limiting telithromycin to community-acquired pneumonia, on-label use was 6.7% (12 CONCLUSION: Despite revised FDA indications and safety warnings, fewer than 1 in 15 active telithromycin users have a medical claim consistent with the only currently approved indication (pneumonia). Pharmacy claims for telithromycin dropped substantially following reports of severe hepatotoxicity and strengthened safety warnings. The high prevalence of telithromycin off-label use despite hepatotoxicity and other safety risks is cause for continued concern. T elithromycin (Ketek) was approved on April 1, 2004 , for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), bacterial sinusitis, and communityacquired pneumonia (CAP). 1 Telithromycin is similar in structure and mechanism of action to macrolides (e.g., clarithromycin). Telithromycin was the first of the ketolide class of antimicrobials approved by the U.S. Food and Drug Administration (FDA) with a mechanism of action inhibiting protein synthesis by binding to domains II and V of the 50S ribosome. 2 This dual mechanism of action allows telithromycin to retain activity against macrolideresistant organisms. This is perceived to be important since penicillin and macrolide nonsusceptible Streptococcus pneumoniae strains continue to increase in prevalence according to in vitro studies. 3, 4 However, the clinical importance of antimicrobial treatment for sinusitis and ABECB is unclear. 5 Due to the unique mechanism of action and spectrum of activity, telithromycin was seen as a potentially valuable outpatient therapy for upper respiratory tract infections (e.g., sinusitis), ABECB, and CAP.
The approval process of telithromycin was controversial. The initial application for approval was rejected by the FDA in June 2001, citing a need for additional safety data. 6 Study 3014 was a randomized controlled trial designed to address safety concerns; it involved more than 24,000 patients. 6, 7 Although study 3014 was completed in 5 months and found that telithromycin was comparable to amoxicillin/clavulanate in terms of safety, a routine FDA inspection uncovered fraud, including fabrication of data and violation of conduct; 4 of the top 10 patient-recruiting sites were referred for criminal investigation. 7 In response to the irregularities of study 3014, the FDA deviated from usual policy and proposed analysis of unreliable foreign postmarketing reports to confirm telithromycin' s safety. 7 In addition to recruiting violations and use of rarely approved safety data, clinical trials studying telithromycin for ABECB and bacterial sinusitis used methodology no longer accepted by the FDA; they were powered for noninferiority, which is no longer recommended. 7 Noninferiority trials are designed to simply identify if a therapy is less effective than the comparator by a predefined maximal margin, and still better than placebo. In 2004, the foreign safety reports combined with specious clinical trial data led to the approval of telithromycin. 6, 7 Severe adverse events associated with telithromycin use arose shortly after approval. A report published in the Annals of Internal Medicine described 3 cases of severe hepatotoxicity in patients treated with telithromycin. 8 Outcomes for the 3 patients varied in severity with one patient recovering upon discontinuation of telithromycin, a second patient requiring liver transplantation, and the third dying of acute liver failure. 8 An analysis of the FDA's postmarketing database revealed a 3.5 to 11 times higher incidence of acute liver failure associated with telithromycin compared with other antimicrobials. 9 A reported rate of 167 cases of acute liver failure per 1 million person-years of telithromycin use has been documented. 9 Additional safety concerns associated with telithromycin use appeared in the literature, including exacerbation or unmasking of myasthenia gravis. 10, 11 Cases occurred shortly after telithromycin administration and would often resolve upon discontinuation of the drug. 10 Visual adverse events including blurred vision, difficulty focusing, and diplopia occur in 0.27% to 2.1% of patients treated with telithromycin. 12 Telithromycin is also a potent inhibitor of CYP3A4, increasing the risk for serious drug-drug interactions. 12 In response to mounting safety concerns, on February 12, 2007, the FDA issued revised labeling and updated safety information for telithromycin. 13 Indications for ABECB and bacterial sinusitis were removed. A black-box warning contraindicating the use of telithromycin in patients with myasthenia gravis was added. Finally, warnings regarding liver toxicity, visual disturbances, and loss of consciousness were strengthened.
Telithromycin presents a unique challenge for managed care. Notification of labeling changes can be slow to reach many providers. As a result, members may continue to be prescribed telithromycin for indications where the benefits are no longer outweighed by the risks. Analysis of pharmacy claims in relation to major events in a drug's life cycle may provide insight as to how effectively information is disseminated and the degree of impact this information has on prescribing practices.
The objective of this study was to assess the prevalence of onlabel telithromycin utilization before and after the revisions of the product label and assess how the occurrence of pivotal events in the medication' s life cycle are reflected in pharmacy claims.
■■ Methods
Using retrospective administrative medical and pharmacy claims from a large midwestern commercial insurer with 1. Members with multiple diagnoses were classified by highest diagnosis on a hierarchical scale. Ranking of diagnosis from highest to lowest were as follows: pneumonia, bronchitis, sinusitis, URI, influenza, asthma, COPD, and cough. For example, a patient with medical diagnoses of pneumonia and cough would be classified as a pneumonia patient. Patients with a medical claim for a diagnosis not listed above were categorized as unspecified.
Pharmacy claims data were analyzed for frequency of occurrence and percent of patients with each corresponding diagnosis on the medical claims. A second analysis of the impact of major events on telithromycin utilization was also conducted. because a suspension formulation of telithromycin is not available. A limited data set was obtained after direct individual identifiers were removed to meet the requirements of HIPAA (Health Insurance Portability and Accountability Act). Consistent with the National Bioethics Advisory Commission exemption of activities considered research, the purpose of these analyses were not intended to generate scientific knowledge but, rather, to improve pharmacy benefit management of drugs with new safety concerns. 15 
■■ Results
During the period of January 1, 2007, to April 13, 2007, 649 claims for telithromycin were filled for 587 members. For 80 of the 587 (13.6%) members, no medical claims were filed within 30 days of their initial telithromycin claim. This left, for our analysis, 507 members with a medical claim indicating the member was seen by a provider within 30 days of the telithromycin pharmacy claim. A medical claim within 7 days of the telithromycin claim was present in 90.3% (458 of 507) members. Using the original FDAapproved telithromycin indications to define an on-label diagnosis, an on-label diagnosis was present for 52.3% (265 of 507) of telithromycin utilizers (Table 1 ). The most common medical diagnosis was sinusitis, which occurred in 172 (33.9%) members, followed by a medical claim lacking a defined ICD9-CM for this study (i.e., pneumonia, bronchitis, sinusitis, URI, influenza, asthma, COPD, or cough) (115 of 507, 22.7%). A medical diagnosis of pneumonia was present for 20 (3.9%) members. Members with a medical claim who filled a telithromycin prescription after the change in telithromycin-approved indications to only pneumonia on February 12, 2007, were analyzed (Table 2) . One hundred seventy-nine members were available for this analysis. An on-label diagnosis of pneumonia was present in 12 (6.7%) members. The majority of these members (61 of 179, 34.1%) had a sinusitis medical diagnosis.
Claims for telithromycin increased rapidly after the product' s launch, surpassing clarithromycin tablets in January 
■■ Discussion
Telithromcyin' s unique mechanism of action, ease of use, and activity against macrolide resistant organisms made this agent an attractive new option for treatment of community-acquired infections. However, safety concerns of liver toxicity, visual disturbances, and myasthenia gravis exacerbations overshadowed the potential benefits. We conducted a retrospective analysis of claims data for telithromycin with emphasis on 2 events: the publication of cases of severe hepatotoxicity and the revised FDA labeling.
Our analysis identified inappropriate telithromycin use before and after the FDA intervention. Sinusitis was the diagnosis in 33.9% of patients overall and 34.1% of members after February 12, 2007 . This implies steady telithromycin utilization for indications that the risks of therapy are now deemed greater than Telithromycin: The Perils of Hasty Adoption and Persistence of Off-Label Prescribing the potential benefits. Pneumonia was the diagnosis in 3.9% of patients. After the FDA action, pneumonia was the diagnosis in only 6.7% of patients despite pneumonia being the only approved indication. Unfortunately, inappropriate antimicrobial use in managed care systems is common. A study by Stallworth et al. found that children with asthma were more likely to receive antimicrobials for illnesses likely caused by viruses such as bronchitis than nonasthmatic children (odds ratio, 3.3, 95% confidence interval, 2.97-3.66). 16 Publication of serious adverse events or safety interventions by the FDA often has a negative effect on number of claims. In our analysis, claims for telithromycin dropped 80% from January 2006 to January 2007 after the publication of case reports regarding severe hepatotoxicity. Although part of this decline could be explained by seasonal changes, the rebound of telithromycin claims The decline in telithromycin use is understandable as the riskto-benefit ratio has been found unacceptable for the treatment of sinusitis and ABECB. Only for the more serious condition of pneumonia has telithromycin been found to have an acceptable risk to benefit ratio. Unfortunately, only 1 of 25 members treated with telithromycin had a documented diagnosis of pneumonia during early 2007.
Managed care organizations have several options to address concerns with telithromycin use. Provider education initiatives including retrospective drug utilization review (DUR) can increase prescriber awareness of new safety warnings. Kaufman et al. used a letter and telephone system to educate providers prescribing contraindicated medications to elderly patients. 19 Incidence of inappropriate medication use declined 19%. 19 Significant reductions in the number of elderly persons who received contraindicated medications and persons receiving 1 or more of 7 contraindicated medications were also documented. 19 We have already begun a retrospective DUR education program for our providers concerning telithromycin. Additional options for managed care organizations to consider would be prior authorization limiting the use of telithromycin to patients with pneumonia who have failed multiple first-line agents, and/or removal of the agent from the formulary.
Limitations
The study was intended to explore potential associations between the FDA safety warning and label change and telithromycin utilization; a direct cause-and-effect link cannot be made. Medical and pharmacy claims data are limited by the nature of the data. The administrative claims data are believed to be an accurate representation of the members' actual medical diagnoses, and we did not perform either chart review or have electronic medical records available to audit absent medical diagnosis information.
Our study assumes that coincident medical claims are linked to the telithromycin claim. The finding that 80 of 587 (13.6%) members lacked a medical claim within 30 days of their initial telithromycin claim appears high, however, members could have interacted with their prescriber outside of the clinic setting (e.g., telephone) resulting in the telithromycin prescription being phoned in to the pharmacy. In addition, we used the date of service field on the pharmacy claim to identify the date the member filled the telithromycin prescription and the date of service field on the medical claim to signify the date the member was seen by the physician. Members may have been instructed to wait or may have on their own delayed filling their telithromycin prescription, in which case we would have misclassified the member as lacking a medical claim within 30 days of their initial telithromycin claim; e.g., a prescription written in mid-January 2007 but not filled until mid-March 2007. However, the majority of coincident medical claims were associated with an infectious illness, and we believe patients are likely to fill prescriptions for antimicrobial medications soon after receiving them. Our data are also limited to a specific geographical region in the Midwest and may not be generalized to Medicare or Medicaid populations or other geographic regions.
■■ Conclusion
New safety concerns led to a more obvious negative risk-to-benefit ratio for telithromycin in the treatment of sinusitis and ABECB. Despite revised FDA indications, use of telithromycin for disease states not listed on the product label is still common. Fewer than 1 in 15 users of telthromycin had a pneumonia diagnosis, the only remaining approved indication. Utilization of telithromycin dropped substantially following reports of severe hepatotoxicity, strengthened safety warnings, and label changes. The high rate of off-label telithromycin use is cause for continued concern. Options available to managed care organizations include retrospective DUR provider education, prior-authorization programs, or formulary removal. Managed care professionals should be proactive in the education of patients and providers to reduce the risk of serious complications associated with telithromycin therapy.
